

Enforc-11021(11)/106/2024-eoffice
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Enforcement Division)

FDA Bhawan, Kotla Road

New Delhi-110002

Date **06 JUL 2026**

NOTICE

Subject: Inviting comments on consideration of the proposal regarding Issue of use of brand name extensions by the pharmaceutical firms -reg.


This Directorate has received representations regarding Issue of use of brand name extensions by the pharmaceutical firms.

In view of above, the issue was deliberated in 6th Drugs Consultative Committee (DCC) meeting on 17.11.2025 and DCC was apprised about a representation received alleging that a pharmaceutical company is marketing multiple drug formulations under the same established brand name with different extensions. Concerns have been raised that the use of the same brand name for drugs with different active ingredients may mislead consumers and create confusion regarding their therapeutic use.

Wherein, DCC deliberated the matter in detail and opined to carry out a stakeholder consultation in the matter considering various aspects.

Accordingly, the recommendations of the Drugs Consultative Committee (DCC) as above are uploaded in CDSCO website for seeking public comments in the matter and all stakeholders may send their comments on or before 17.07.2026 vide email id's: **enforcecell.div@cdsco.nic.in** for further necessary action in the matter.

Yours faithfully,


Dr. Rajeev Singh Raghuvanshi
Drugs Controller General (India)

To: All Stakeholders through CDSCO website